MSLP.OB, HLF, SLXP Helping Athletes Acheive Success

PRLog (Press Release) - Aug 24, 2010 -
MusclePharm Corporation (OTCBB:MSLP.OB), one of the fastest growing nutritional supplement companies in the United States with a proprietary formulation used in eight performance products, announced the appointment of Mariel Selbovitz, MPH, as Director of Global Therapeutics Product Procurement Development.

PEPFAR was launched in 2003 by President George W. Bush, and is the largest effort by any nation to combat a single disease with $18 billion dollars dedicated to fight HIV/AIDS in developing nations over the five year period of 2003-2008. In the first five years of the program, PEPFAR focused on establishing and scaling up prevention, care and treatment programs. It achieved success in expanding access to HIV prevention, care and treatment in low-resource settings.

By securing procurement of the Global Fund and PEPFAR, MusclePharm will be able to distribute Recon and other supplements to millions of people with HIV/AIDS worldwide thru government funds. In July 2010, MusclePharm presented at the 18th International AIDS Conference on the benefits of Recon in people with HIV/AIDS, sponsored by the National Association of People with AIDS and the AIDS Institute, both leading HIV legislative and advocacy organizations.

MusclePharm’s top management has extensive experience in the sports world and has harnessed this drive and focus into building a business to benefit its customers and help Fuel The Athlete Inside. Headquartered in Aurora, Colorado, MusclePharm is a fast-growing developer and manufacturer of safe, scientifically approved, nutritional supplements that are free of banned substances and tested by athletes. They are designed to help athletes, bodybuilders, weightlifters and fitness enthusiasts improve their performance. Each and every MusclePharm product is the end result of an advanced six-stage research and testing protocol involving the expertise of top nutrition scientists.



Herbalife Ltd. (NYSE:HLF) announced three sponsorship agreements to extend its branding efforts around the world.

HLF became an official sponsor of top Israeli football team, Maccabi Haifa FC. As Official Sponsor for Sports Nutrition, Herbalife will work with the team’s doctors to provide nutritional advice and products to the team as part of their overall training regime.

The two-year deal will see the Herbalife logo appear on all Maccabi Haifa match and training kit shorts. In addition, the Herbalife brand will be showcased in the Kiryat Eliezer, Maccabi Haifa’s home stadium, and in the team’s training facilities; as well as through Maccabi Haifa’s official media channels and on the team bus.

Herbalife Ltd., a network marketing company, sells weight management, nutritional supplement, energy, sports and fitness, and personal care products worldwide. It offers science based products in four principal categories: weight management; targeted nutrition; energy, sports, and fitness; and outer nutrition. The companys weight management product portfolio includes meal replacement shakes, weight-loss enhancers, appetite suppressors, and a range of healthy snacks. Its targeted nutrition products comprise dietary supplements, which contain herbs, vitamins, minerals, and natural ingredients that support good health. The companys energy, sports, and fitness products consist of energy and isotonic drinks to support a healthy active lifestyle.



Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) recently announced the U.S. Food and Drug Administration has accepted for Priority Review the Company’s efficacy supplement to the New Drug Application for XIFAXAN 550 mg tablets for the proposed indication of treatment of non-constipation irritable bowel syndrome and IBS-related bloating. Non-constipation irritable bowel syndrome encompasses two of the most common IBS subtypes: patients with diarrhea-predominant symptoms and patients who suffer from intermittent periods of diarrhea and constipation known as mixed IBS.

Salix Pharmaceuticals, Ltd., headquartered in Raleigh, North Carolina, develops and markets prescription pharmaceutical products for the prevention and treatment of gastrointestinal diseases. Salix’s strategy is to in-license late-stage or marketed proprietary therapeutic drugs, complete any required development and regulatory submission of these products, and market them through the Company’s gastroenterology specialty sales and marketing team.

Sign Up for our Free Stock Newsletter at http://www.pennyotcstock.com/signup





THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. PennyOtcStock.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold PennyOmega.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://pennyotcstock.com/disclaimer) Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (CRWE.OB) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock.Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period. Crown Equity Holdings Inc. (CRWE.OB) has received twenty five thousand dollars in cash and seventy five thousand free trading shares from a third party (Bishop Equity Partners) for (30) days of advertising for Muscle Pharm Corp. (MSLP.OB).